CA
NZ
UK
AU
IND
US
…
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alterity Therapeutics is a clinical-stage Australian biotechnology company developing small-molecule therapies that target metal dysregulation and alpha-synuclein aggregation in neurodegenerative diseases, with lead candidate ATH434 focused on Parkinsonian disorders and related synucleinopathies. Long-term growth may be driven by clinical progress for ATH434, biomarker-guided development and potential licensing or partnering opportunities that could support advancement toward disease-modifying treatments.
Key investment risks include high clinical and regulatory failure probability, ongoing financing needs that may dilute shareholders, and significant competition from other neurodegenerative drug programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -26.90M | -12.08M | -19.08M | -13.70M | -12.78M |
| Net income | -23.40M | -12.15M | -19.12M | -13.81M | -12.85M |
| Selling general administrative | - | 5.48M | 4.77M | 4.94M | 5.46M |
| Selling and marketing expenses | - | - | -0.01M | 0.05M | - |
| Gross profit | -0.12M | 5.31M | 3.80M | 3.63M | - |
| Reconciled depreciation | - | 0.14M | 0.15M | 0.10M | 0.05M |
| Ebit | -28.42M | -14.66M | -19.61M | -15.29M | -17.86M |
| Ebitda | -28.30M | -14.63M | -19.46M | -15.19M | -17.81M |
| Depreciation and amortization | 0.12M | 0.03M | 0.15M | 0.10M | 0.05M |
| Operating income | -28.42M | -14.57M | -19.60M | -14.64M | -17.86M |
| Other operating expenses | 28.42M | 20.01M | 23.62M | 14.35M | 15.14M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | - | 0.07M | 0.05M | 0.10M | 0.07M |
| Interest income | - | 0.45M | 0.27M | 0.02M | 0.00M |
| Net interest income | - | 0.45M | 0.27M | 0.02M | 0.00M |
| Income tax expense | -3.50M | 0.07M | 0.05M | 0.10M | 0.07M |
| Total revenue | - | 5.44M | 4.02M | 3.92M | 0.00M |
| Total operating expenses | 28.30M | 19.89M | 23.41M | 14.35M | 15.14M |
| Cost of revenue | 0.12M | 0.13M | 0.21M | 0.29M | - |
| Total other income expense net | 1.52M | 2.49M | 0.52M | 0.65M | 5.08M |
| Net income from continuing ops | - | -12.15M | -19.12M | -13.81M | -12.85M |
| Net income applicable to common shares | - | -12.15M | -19.12M | -13.81M | -12.85M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 46.02M | 46.03M | 19.22M | 27.32M | 41.36M |
| Other current assets | 0.81M | 0.04M | 2.36M | 0.04M | 0.01M |
| Total liab | 3.29M | 3.62M | 5.43M | 4.50M | 5.89M |
| Total stockholder equity | 42.72M | 42.40M | 13.80M | 22.81M | 35.47M |
| Other current liab | 1.98M | 0.00M | 4.67M | 2.67M | -0.03M |
| Common stock | 282.51M | - | 223.15M | 213.97M | 213.79M |
| Capital stock | - | 262.95M | - | 213.97M | 213.79M |
| Retained earnings | -245.58M | -225.89M | -214.16M | -195.13M | -181.88M |
| Other liab | - | - | - | 0.02M | 0.01M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 37.32M | 33.16M | 12.64M | 15.77M | 34.81M |
| Cash and equivalents | - | - | - | - | 34.81M |
| Total current liabilities | 3.16M | 3.53M | 5.37M | 4.38M | 5.82M |
| Current deferred revenue | - | - | 0.02M | -0.11M | 3.10M |
| Net debt | -37.12M | - | -12.48M | -15.56M | -34.69M |
| Short term debt | 0.06M | - | 0.11M | 0.11M | 0.06M |
| Short long term debt total | 0.19M | - | 0.16M | 0.21M | 0.12M |
| Other stockholder equity | - | - | - | -18.84M | -31.90M |
| Property plant equipment | - | - | - | 0.27M | 0.22M |
| Total current assets | 45.83M | 45.87M | 19.04M | 27.05M | 41.14M |
| Net tangible assets | - | - | - | 22.81M | 35.47M |
| Short term investments | - | 7.50M | - | - | - |
| Net receivables | 7.70M | - | 4.04M | 8.67M | 4.73M |
| Inventory | - | - | 0.00M | 2.57M | 1.60M |
| Accounts payable | 1.12M | 0.54M | 0.58M | 1.72M | 2.69M |
| Accumulated other comprehensive income | 5.80M | - | 4.81M | - | 3.57M |
| Non currrent assets other | - | - | -0.00M | -0.27M | -0.22M |
| Non current assets total | 0.19M | 0.16M | 0.19M | 0.27M | 0.22M |
| Capital lease obligations | - | 0.16M | - | 0.21M | 0.12M |
| Long term debt total | - | - | - | - | 0.06M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -7.50M | -0.01M | -0.01M | -0.09M |
| Change to liabilities | - | - | - | -1.56M | 2.60M |
| Total cashflows from investing activities | 7.50M | -7.50M | -0.01M | -0.04M | -0.09M |
| Net borrowings | - | -0.13M | -0.01M | -0.06M | -0.03M |
| Total cash from financing activities | 19.13M | 39.67M | 9.22M | 0.12M | 16.30M |
| Change to operating activities | - | - | - | -0.89M | -0.39M |
| Net income | -23.40M | -12.15M | -19.12M | -13.81M | -12.85M |
| Change in cash | 4.16M | 20.52M | -3.13M | -19.03M | 6.69M |
| Begin period cash flow | 33.16M | 12.64M | 15.77M | 34.81M | 28.12M |
| End period cash flow | 37.32M | 33.16M | 12.64M | 15.77M | 34.81M |
| Total cash from operating activities | -22.52M | -11.45M | -12.61M | -20.04M | -12.34M |
| Issuance of capital stock | - | 42.57M | 10.14M | 0.31M | 17.18M |
| Depreciation | 0.12M | 0.14M | 0.15M | 0.10M | 0.05M |
| Other cashflows from investing activities | - | -7.50M | 0.00M | -0.03M | -0.03M |
| Dividends paid | - | - | - | 0.00M | 0.00M |
| Change to inventory | - | - | - | 2.45M | -2.21M |
| Change to account receivables | -3.76M | 0.10M | 4.62M | -3.94M | -0.45M |
| Sale purchase of stock | - | 42.57M | 10.14M | 0.32M | 17.18M |
| Other cashflows from financing activities | -0.14M | -2.77M | -0.92M | -0.13M | -0.84M |
| Change to netincome | - | - | - | 0.06M | -1.31M |
| Capital expenditures | 22.52M | 0.00M | 0.01M | 0.01M | 0.09M |
| Change in working capital | -3.70M | -0.61M | 5.75M | -3.94M | -0.45M |
| Stock based compensation | - | 0.98M | 0.88M | 0.97M | 1.51M |
| Other non cash items | 4.46M | 0.19M | -0.26M | -6.35M | 0.46M |
| Free cash flow | - | -11.45M | -12.61M | -20.04M | -12.43M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATH Alterity Therapeutics Ltd |
-0.03 10.00% |
0.27 | - | 10.33 | 16.82 | 1.55 | 164.75 | 1.13 |
| CSL CSL Ltd |
-0.04 0.02% |
200.73 | - | 22.57 | 6.15 | 4.48 | 4.82 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.13 0.93% |
13.80 | 93.87 | 166.67 | 5.37 | 6.37 | 3.85 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
0.36 1.51% |
24.20 | 154.93 | 36.36 | 42.38 | 7.52 | 31.95 | 160.40 |
| MSB Mesoblast Ltd |
0.04 1.96% |
2.08 | - | 454.55 | 23.43 | 3.36 | 18.28 | -9.86 |
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Geoffrey Paul Kempler B.Sc, B.Sc. | Co-Founder & Non-Exec. Chairman | 1955 |
| Dr. David A. Stamler M.D. | Chief Exec. Officer | 1961 |
| Ms. Kathryn J. E. Andrews | Chief Financial Officer | 1967 |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of R&D Advisory Board | 1958 |
| Dr. Steven D. Targum | Chief Medical Advisor | NA |
| Dr. Robert Cherny | Head of Research | NA |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | Company Sec. | 1959 |
| Mr. Geoffrey Paul Kempler B.Sc. | Co-Founder & Non-Executive Chairman | 1955 |
| Dr. David A. Stamler M.D. | Chief Executive Officer | 1961 |
| Ms. Kathryn J. E. Andrews B.Com, CPA | Chief Financial Officer | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.07%
Communication Services
-0.42%
Consumer Cyclical
-0.41%
Consumer Defensive
-0.22%
Energy
-0.09%
Financial Services
-0.14%
Financials
-0.48%
Healthcare
-0.22%
Industrials
-0.11%
Real Estate
-0.53%
Technology
-0.23%
Utilities
-0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+1.15%
Please wait processing your request...